Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Food Allergy
- Peanut Allergy
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 7 years and 25 years
- Gender
- Both males and females
Description
36 subjects will receive Xolair, and 8 subjects will receive placebo. The study will occur at 4 sites: Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University and Lurie Children's Hospital. Patients will be pre-treated with Xolair or placebo before rapid oral peanut dese...
36 subjects will receive Xolair, and 8 subjects will receive placebo. The study will occur at 4 sites: Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University and Lurie Children's Hospital. Patients will be pre-treated with Xolair or placebo before rapid oral peanut desensitization. Patients will continue to receive Xolair during the 8 subsequent weeks of desensitization, receiving their final dose of Xolair one week after reaching the highest tolerated dose of peanut.
Tracking Information
- NCT #
- NCT01781637
- Collaborators
- Children's Hospital of Philadelphia
- Stanford University
- Ann & Robert H Lurie Children's Hospital of Chicago
- Investigators
- Principal Investigator: Lynda C Schneider, MD Boston Children's Hospital Study Chair: Andrew MacGinnitie, MD, PhD Children' Hospital Boston Study Chair: Kari Nadeau, MD, PhD Stanford University Study Chair: Jonathan Spergel, MD, PhD Children's Hospital of Philadelphia Study Chair: Jacqueline Pongracic, MD Lurie Children's Hospital
Get Well Soon